|Mr. Joshua T. Brumm||Pres, CEO, Treasurer, Sec. & Director||277.31k||N/A||1978|
|Dr. Romesh Subramanian Ph.D.||Co-Founder & Chief Scientific Officer||411.66k||N/A||1965|
|Dr. Jonathan McNeill M.D.||VP of Bus. Devel.||302.62k||N/A||N/A|
|Mr. Jason P. Rhodes M.B.A.||Co-Founder & Independent Chairman||N/A||N/A||1970|
|Mr. Gene Kim||VP of Fin.||N/A||N/A||1976|
|Ms. Susanna Gatti High M.B.A.||Chief Operating Officer||N/A||N/A||1968|
|Mr. Richard Scalzo||VP of Accounting & Admin.||N/A||N/A||1986|
|Ms. Amy Reilly||VP of Corp. Communications & Investor Relations||N/A||N/A||1973|
|Dr. Oxana Beskrovnaya Ph.D.||Sr. VP & Head of Research||N/A||N/A||1961|
|Dr. Thomas-Christian Mix M.D.||Sr. VP of Clinical Devel.||N/A||N/A||1967|
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapies. The company was founded in 2017 and is based in Waltham, Massachusetts.
Dyne Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.